可重复使用先进止血装置(Vi-Sealer)在韩国全腹腔镜子宫切除术中的疗效与安全性评估(KGOG4009/Vi-TLH试验):多中心、开放标签、非劣效性随机对照试验研究方案
本研究为多中心、开放标签、非劣效性随机对照试验,计划纳入280例因良性妇科疾病行全腹腔镜子宫切除术的患者,比较可重复使用Vi-Sealer与其他先进止血装置。主要终点为手术时间,非劣效性界值为25分钟(20%)。研究旨在评估Vi-Sealer的疗效、安全性和成本,目前处于招募阶段。
要点
- Vi-Sealer为可重复使用先进止血装置,旨在降低单次使用装置带来的手术成本。
- 主要终点为手术时间,非劣效性界值设为25分钟(20%)。
- 患者按竞争装置分层为两个队列,每队列140例,1:1随机分配。
核心结论
- 本研究将评估可重复使用Vi-Sealer在全腹腔镜子宫切除术中的疗效、安全性和成本分析,通过与其他先进止血装置比较,预期提供可靠证据以确定Vi-Sealer是否非劣效于一次性先进止血装置。
研究设计与样本
- 多中心、开放标签、非劣效性随机对照试验,计划纳入280例因良性妇科疾病行全腹腔镜子宫切除术的患者,假设手术时间非劣效性界值为25分钟(20%)。
- 纳入子宫或浸润前宫颈病理病例,排除巨大肿瘤尺寸者;按竞争装置分层为两个队列,每队列140例,1:1随机分配至Vi-Sealer或对照装置(队列1为LigaSure,队列2为其他先进止血装置)。
- 研究在韩国大学附属医院开展,招募在妇科门诊进行,计划于2022年11月开始入组;参与者设盲,外科医生因手术性质不设盲。
- 主要终点为手术时间(分钟),定义为从初始皮肤切口至皮肤缝合完成;次要终点包括失血量(mL)、医疗费用(韩元)、手术医生装置功能评分和不良事件;各队列分别分析。
- 不良事件和并发症按CTCAE临床评估至术后随访;试验注册于ClinicalTrials.gov(NCT05629611,2022年11月29日)和cris.nih.go.kr(KCT0008008,2022年12月13日)。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Advanced hemostatic devices (AHDs) are widely utilized in gynecologic minimally invasive surgeries. These AHDs control ultrasonic or bipolar electric/thermal energy with a feedback mechanism and effectively seal vessels without thermal spread. However, most AHDs are single-use, potentially increasing surgical costs. Vi-Sealer, a reusable AHD with an interchangeable blade, aims to address this issue. This study assesses operative outcomes and complications to evaluate the efficacy and safety of Vi-Sealer compared to other AHDs. METHODS: This multicenter, open-label, non-inferiority, randomized controlled trial compares Vi-Sealer with other AHDs in 280 patients undergoing total laparoscopic hysterectomy (TLH) for benign gynecologic diseases, assuming a 25-min (20%) non-inferiority margin in operative time. Cases with uterine or preinvasive cervical pathology were included, while those with huge tumor size were excluded. Participants are stratified into two cohorts based on competing devices. Each cohort consists of 140 participants, randomized in a 1:1 ratio to undergo TLH with either Vi-Sealer or a comparator device-LigaSure in cohort 1 and other AHDs in cohort 2. This study will be conducted at university-affiliated hospitals in South Korea, where recruitment will be carried out within the gynecology clinics. The enrollment is planned to begin in November 2022. Participants will be blinded, whereas surgeons will not be due to the nature of surgery. The primary endpoint is operation time (min) defined as the duration of the initial skin incision to the completion of skin closure, while secondary endpoints include blood loss (mL), medical cost (won), operating surgeons' device function scores, and adverse events. Outcomes will be analyzed separately for each cohort. Adverse events and complications will be assessed clinically until postoperative follow-up, per CTCAE. This trial is currently in the recruitment phase with active enrollment ongoing. DISCUSSION: This study will evaluate the efficacy, safety, and cost analysis of the reusable Vi-Sealer in TLH. Through the comparison of AHDs, this is expected to provide robust evidence to determine whether the Vi-Sealer is non-inferior to disposable AHDs. TRIAL REGISTRATION: This study was registered on ClinicalTrials.gov (NCT05629611) on November 29, 2022 ( https://clinicaltrials.gov/study/NCT05629611?intr=vi-sealer&rank=1 ) and cris.nih.go.kr (KCT0008008) on December 13, 2022 ( https://cris.nih.go.kr/cris/search/detailSearch.do?seq=23737&search_page=L ). This is currently open for enrollment.
引用
- Kim M, Seong SJ, Kim K, et al. Efficacy and safety evaluation of a reusable advanced hemostatic device (Vi-Sealer) during total laparoscopic hysterectomy in South Korea (KGOG4009/Vi-TLH trial): study protocol for a multicenter, open-label, non-inferiority randomized controlled trial. Trials. 2025. PMID: 41204237. doi:10.1186/s13063-025-09222-w
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。